NewEdge Advisors’s DMK Pharmaceuticals Corporation Common Stock DMK Stock Holding History

NewEdge Advisors’s Portfolio DMK Stock Details DMK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-38	Closed	-$27	–	4004
2023 Q4	$27	Hold	38	–	–	﹤0.01%	3690
2023 Q3	$26	Hold	38	–	–	﹤0.01%	3421
2023 Q2	$92	Sell	38 -1	-3%	-$4	﹤0.01%	3425
2023 Q1	$313	Hold	39	–	–	﹤0.01%	3284
2022 Q4	$0	Buy	+39	New	+$446	﹤0.01%	4246

Other funds holding DMK

CPA

Clear Point Advisors Melville, New York $129M AUM 12.02% 1-Year Est. Return

OPTFSNA

Old Point Trust & Financial Services N A Newport News, Virginia $311M AUM 24.14% 1-Year Est. Return

NewEdge Advisors's DMK Position: Q1 2024 in Review

NewEdge Advisors sold out of DMK Pharmaceuticals Corporation Common Stock (DMK) in Q1 2024, closing a stake of 38 shares — an estimated $27 sold.

NewEdge Advisors first reported a position in DMK in Q4 2022 and held it in 5 quarters. The position peaked at $313 in Q1 2023. 3 funds tracked by Wall St. Rank hold DMK as of Q1 2024.

NewEdge Advisors reported no remaining DMK Pharmaceuticals Corporation Common Stock position as of Q1 2024 after selling out during the quarter.
NewEdge Advisors sold 38 DMK Pharmaceuticals Corporation Common Stock shares in Q1 2024, an estimated $27.
NewEdge Advisors first reported a position in DMK Pharmaceuticals Corporation Common Stock in Q4 2022 and held it in 5 quarters.
NewEdge Advisors's DMK Pharmaceuticals Corporation Common Stock position peaked at $313 in Q1 2023.
3 funds tracked by Wall St. Rank held DMK Pharmaceuticals Corporation Common Stock as of Q1 2024.

Based on NewEdge Advisors's 13F filing for Q1 2024, filed 14 May 2024.